Venous thromboembolism treatment market outlook - 2027
Venous thromboembolism (VTE) is a condition in which a blood clot forms most often in the deep veins of the leg, groin or arm (known as deep vein thrombosis, DVT) and travels in the circulation, lodging in the lungs (known as pulmonary embolism, PE). Together, DVT and PE are known as VTE - a dangerous, potentially deadly medical condition. VTE is a leading cause of death and disability worldwide. A comprehensive scientific review by the WTD steering committee revealed that 10 million cases of VTE occur annually across low, middle and high income countries. Anticoagulant and thrombolytic therapy options are available for the treatment of venous thromboembolism (VTE). Anticoagulant therapy prevents further clot deposition and allows the patient’s natural fibrinolytic mechanisms to lyse the existing clot. Anticoagulant inpatient medications should include heparin or a low-molecular-weight heparin (LMWH), followed by the initiation of an oral coumarin derivative. Growing demand for venous thromboembolism treatment devices is anticipated to drive for venous thromboembolism treatment industry growth over the coming years.
Covid-19 Scenario analysis:
The coronavirus COVID-19 is affecting 213 countries and territories around the world. COVID-19 has created new challenges that are requiring manufacturers to innovate at speeds they never have before. Supply chain disruptions, social distancing on high-touch assembly lines, limited ability to travel, and the need for oversight add significant complexity to today’s processes. The outbreak of coronavirus disease 2019 (COVID-19) has created a global health crisis that has had a deep impact on the manufacturing market there is a shortage in supply of raw materials from Chinese manufacturers which has resulted in a severe demand-supply gap. The manufacturers are further expected to be stranded on raw material orders owing to the logistics industry being significantly impacted due to lockdown amid COVID-19. There has also been a shortage of beds in hospital as the majority of beds are assigned to COVID-19 patients who require critical care. This has all affected the market adversely causing a slowdown in the venous thromboembolism treatment market due to shortage of workforce, supply and manufacturing.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact analysis:
Drivers:
Increased Cardiac diseases prevalence:
Venous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary embolism, is a common disorder with at least 250,000 new events occurring each year in the United States alone. Treatment of VTE entails anticoagulation, which is achieved initially with the use of a parentally administered anticoagulant followed by a more prolonged course of treatment with an oral vitamin K antagonist. The duration of anticoagulation depends on the clinical assessment of the benefit-risk ratio of prolonged anticoagulation versus the risk of recurrent events. Venous thromboembolism (VTE) is a term that encompasses both deep vein thrombosis (DVT) and pulmonary embolus (PE). VTE is a common disorder, and although there are remaining uncertainties about its precise incidence, it accounts for at least 250,000 and as many as 900,000 incident cases per annum in the United States. When compared to the other major cardiovascular thrombotic disorders, the incidence of VTE is very similar to the incidence of fatal or non-fatal stroke or myocardial infarction. The diagnosis of VTE can be challenging, requiring an algorithmic approach combining the degree of clinical suspicion, and objective appropriately validated laboratory markers (such as plasma D-dimer) and radiologic studies. The clinical presentation of about two thirds of patients is with DVT, while the remaining one third present with PE. However, since occult PE is common in patients presenting with DVT (and vice versa), DVT and PE are currently considered to be complementary manifestations of the same pathophysiologic process. Thus the increase in the prevalence of VTE it is evident that there will be market growth in the near future.
Technological advancements for treatments:
The introduction of low molecular weight heparins and related inhibitors of factor Xa (such as the pentasaccharide Fondaparinux™) have arguably addressed the clinical need for better parenteral anticoagulants. These agents have superior bioavailability and reduced need for monitoring compared to unfractionated heparin. However, the need for orally available anticoagulants to replace warfarin and other vitamin K antagonists in the secondary prophylaxis of VTE persists. Warfarin was introduced into clinical practice in 1954, and to this day it remains the only licensed oral agent for the treatment of VTE. The limitations of the oral vitamin K antagonists include their slow onset of action, the variability of dosing between individuals resulting in part from genetic polymorphisms in warfarin’s metabolic pathways, and the fact that frequent monitoring is required to manage food and drug interactions, which are often unpredictable. In addition, like many anticoagulants, warfarin suffers from a relatively narrow therapeutic window that necessitates careful monitoring. Thus, major bleeding events were twice as common in studies targeting an INR >3.0 compared to those targeting the most commonly used target range of 2.0–3.0, and an INR >4.5 is a strong independent risk factor for bleeding, with an odds ratio of almost 6. More importantly, major bleeding associated with anticoagulant therapy is frequently associated with poor clinical outcomes. For example, in the RIETE Registry, the all-cause mortality in the 2–3% of patients developing major bleeding during treatment for VTE was 33%, of whom about half died as a direct result of the hemorrhagic event. While these numbers may appear high relative to the published clinical trials, their validity is supported by community-based studies that likely are more representative of the ‘real world’ experience with warfarin-induced bleeding. The advancements and research will boost market growth. Also, increasing demand for cost-effective treatment are aspects expected to accelerate business growth. Additionally, growing retrieval rate of inferior vena cava filters boost growth.
Restrains:
The pharmacological agents used in the treatment of VTE are all considered to be “high risk” drugs. The National Patient Safety Agency is undertaking a stakeholder consultation on the safe use of anticoagulants and is due to issue guidance later this year. In the consultation document the NPSA has identified several high-risk areas, including staff competency, training, guidelines, communication and patient information.
Key benefits of the report:
- This study presents the analytical depiction of the global venous thromboembolism treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global venous thromboembolism treatment market share.
- The current market is quantitatively analyzed to highlight the global venous thromboembolism treatment market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global venous thromboembolism treatment market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the venous thromboembolism treatment Market research report:
- Who are the leading market players active in the venous thromboembolism treatment market?
- What the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in taking further strategic steps?
Venous thromboembolism treatment market: Global Opportunity Analysis and Industry Forecast, 2025-2032, by Product Report Highlights
| Aspects | Details |
 By Product |
|
 By Indication |
|
 By End User |
|
 By Region |
|
 Key Market Players | Boston Scientific, Argon Medical Devices, DJO Global, Stryker, Cook Medical, Arjo, Koninklijke Philips N.V, Cardinal Health (Medtronic), Bristol-Myers Squibb Company |
 Other Players | Sanofi S.A. |
Loading Table Of Content...
